Freenome, founded in South San Francisco, aims to revolutionize cancer detection, treatment, and prevention. The company leverages cutting-edge science and artificial intelligence to develop an intelligent screening platform that uses multiomics technology. This platform enables the early detection of cancer through a simple blood draw, making it easier to identify the disease at its most treatable stages. Freenome's mission is to outpace cancer by setting a new standard for early detection, ultimately improving patient outcomes and saving lives.

Notable figures associated with Freenome include Co-founder and Chief Product Officer Riley Ennis. The company has attracted significant investment from leading venture capital firms and healthcare investors, underscoring its potential impact. Key achievements include the development of their multiomics technology and successful clinical trials demonstrating the efficacy of their screening platform. Freenome's innovative approach has positioned it as a leader in the early cancer detection space, contributing significantly to advancements in oncology diagnostics.